| Shully Salman, | |
|
12301 Califa St, Valley Village, CA 91607-1106 | |
| (310) 500-5193 | |
| Not Available |
| Full Name | Shully Salman |
|---|---|
| Gender | Male |
| Speciality | Clinical Psychologist |
| Experience | 12 Years |
| Location | 12301 Califa St, Valley Village, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1558695049 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 103TC0700X | Psychologist - Clinical | 27314 (California) | Primary |
| Entity Name | Foothills Psychological Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1336121888 PECOS PAC ID: 9436157534 Enrollment ID: O20100318000835 |
News Archive
The Alcon Independent Director Committee noted today that Alcon once again delivered strong earnings in the second quarter of 2010. Alcon's 2Q 2010 Adjusted EPS of $2.22 per share represented a year-over-year growth rate of 14.4% and exceeded Wall Street's mean consensus estimate of $2.03 per share by 9.4%. Alcon's strong EPS growth was driven by an 11.3% increase in organic sales resulting, in part, from a 22.3% increase in advanced technology intraocular lens sales, a 17.2% increase in glaucoma sales and a 24.2% increase in emerging market sales.
Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today announced the full efficacy and safety data from its Phase 3 SPEAR (Study of Picoplatin Efficacy After Relapse) trial of picoplatin in the second-line treatment of small cell lung cancer (SCLC).
NMDARs (N-methyl-D-aspartate receptors) serve as valves on nerve cells, controlling the flow of electrical signals in the brain.
The Lupus Foundation of America (LFA) spearheaded a four-year worldwide initiative with more than 120 lupus experts from 11 countries, the pharmaceutical and biotechnology industries, and federal agencies, which resulted in the first-ever global definition of a lupus flare. The development of Lupus Foundation of America Flare Definition (LFA-Flare) helps to overcome long-standing barriers to the development of new, safe, and more tolerable treatments for lupus.
› Verified 7 days ago
| Entity Name | Change Within Reach Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003207002 PECOS PAC ID: 2062723810 Enrollment ID: O20150619000776 |
News Archive
The Alcon Independent Director Committee noted today that Alcon once again delivered strong earnings in the second quarter of 2010. Alcon's 2Q 2010 Adjusted EPS of $2.22 per share represented a year-over-year growth rate of 14.4% and exceeded Wall Street's mean consensus estimate of $2.03 per share by 9.4%. Alcon's strong EPS growth was driven by an 11.3% increase in organic sales resulting, in part, from a 22.3% increase in advanced technology intraocular lens sales, a 17.2% increase in glaucoma sales and a 24.2% increase in emerging market sales.
Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today announced the full efficacy and safety data from its Phase 3 SPEAR (Study of Picoplatin Efficacy After Relapse) trial of picoplatin in the second-line treatment of small cell lung cancer (SCLC).
NMDARs (N-methyl-D-aspartate receptors) serve as valves on nerve cells, controlling the flow of electrical signals in the brain.
The Lupus Foundation of America (LFA) spearheaded a four-year worldwide initiative with more than 120 lupus experts from 11 countries, the pharmaceutical and biotechnology industries, and federal agencies, which resulted in the first-ever global definition of a lupus flare. The development of Lupus Foundation of America Flare Definition (LFA-Flare) helps to overcome long-standing barriers to the development of new, safe, and more tolerable treatments for lupus.
› Verified 7 days ago
| Entity Name | Shully Salman Psyd A Psychological Corp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619412194 PECOS PAC ID: 1153604640 Enrollment ID: O20170207002198 |
News Archive
The Alcon Independent Director Committee noted today that Alcon once again delivered strong earnings in the second quarter of 2010. Alcon's 2Q 2010 Adjusted EPS of $2.22 per share represented a year-over-year growth rate of 14.4% and exceeded Wall Street's mean consensus estimate of $2.03 per share by 9.4%. Alcon's strong EPS growth was driven by an 11.3% increase in organic sales resulting, in part, from a 22.3% increase in advanced technology intraocular lens sales, a 17.2% increase in glaucoma sales and a 24.2% increase in emerging market sales.
Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today announced the full efficacy and safety data from its Phase 3 SPEAR (Study of Picoplatin Efficacy After Relapse) trial of picoplatin in the second-line treatment of small cell lung cancer (SCLC).
NMDARs (N-methyl-D-aspartate receptors) serve as valves on nerve cells, controlling the flow of electrical signals in the brain.
The Lupus Foundation of America (LFA) spearheaded a four-year worldwide initiative with more than 120 lupus experts from 11 countries, the pharmaceutical and biotechnology industries, and federal agencies, which resulted in the first-ever global definition of a lupus flare. The development of Lupus Foundation of America Flare Definition (LFA-Flare) helps to overcome long-standing barriers to the development of new, safe, and more tolerable treatments for lupus.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Shully Salman, 12301 Califa St, Valley Village, CA 91607-1106 Ph: (310) 500-5193 | Shully Salman, 12301 Califa St, Valley Village, CA 91607-1106 Ph: (310) 500-5193 |
News Archive
The Alcon Independent Director Committee noted today that Alcon once again delivered strong earnings in the second quarter of 2010. Alcon's 2Q 2010 Adjusted EPS of $2.22 per share represented a year-over-year growth rate of 14.4% and exceeded Wall Street's mean consensus estimate of $2.03 per share by 9.4%. Alcon's strong EPS growth was driven by an 11.3% increase in organic sales resulting, in part, from a 22.3% increase in advanced technology intraocular lens sales, a 17.2% increase in glaucoma sales and a 24.2% increase in emerging market sales.
Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today announced the full efficacy and safety data from its Phase 3 SPEAR (Study of Picoplatin Efficacy After Relapse) trial of picoplatin in the second-line treatment of small cell lung cancer (SCLC).
NMDARs (N-methyl-D-aspartate receptors) serve as valves on nerve cells, controlling the flow of electrical signals in the brain.
The Lupus Foundation of America (LFA) spearheaded a four-year worldwide initiative with more than 120 lupus experts from 11 countries, the pharmaceutical and biotechnology industries, and federal agencies, which resulted in the first-ever global definition of a lupus flare. The development of Lupus Foundation of America Flare Definition (LFA-Flare) helps to overcome long-standing barriers to the development of new, safe, and more tolerable treatments for lupus.
› Verified 7 days ago
Jason Matthew Villalobos, Psychologist Medicare: Not Enrolled in Medicare Practice Location: 12501 Chandler Blvd Ste 102, Valley Village, CA 91607 Phone: 818-821-6012 | |
Karen E Lenier, PHD Psychologist Medicare: Accepting Medicare Assignments Practice Location: 12840 Riverside Drive, Suite 200, Valley Village, CA 91607 Phone: 818-413-3560 Fax: 818-901-0975 | |
Rande Dorn, Psychologist Medicare: Not Enrolled in Medicare Practice Location: 12722 Riverside Dr Ste 104, Valley Village, CA 91607 Phone: 818-599-2522 | |
Miriam B Collins, PSYD MFT Psychologist Medicare: Not Enrolled in Medicare Practice Location: 5812 Alcove Ave, Valley Village, CA 91607 Phone: 818-763-8222 | |
Zalman Perlman, Psychologist Medicare: Not Enrolled in Medicare Practice Location: 12501 Chandler Blvd Ste 102, Valley Village, CA 91607 Phone: 818-821-6012 | |
Jody Kussin, PH.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 12609 Killion St, Valley Village, CA 91607 Phone: 818-414-2279 | |
Dr. Bryce Mcdavitt, PHD Psychologist Medicare: Not Enrolled in Medicare Practice Location: 11935 Kling St Apt 9, Valley Village, CA 91607 Phone: 323-317-5235 |